Fautrel reports mixed response to JAK Inhib. in 8 refractory Adult (6) & juvenile (2)-Onset Still's Dz w/ dz Dz duration 86 mos (7 Systemic, 1 Chr articular) w/ JAKi (Bari 4, Upa1, Tofa 2, Ruxo 2). There were no remissions, 50% had partial response @ 11 mos #ACR21 Abstr#0195 https://t.co/Ww8ONBrRqq

#ACR21 #Abstr0252 Let's examine our patients than relying on tests. In sJIA pts presenting with fever, clinical features (fever pattern, rash and MSK symptoms) distinguished inflammation vs infection but not CRP, ferritin and procalcitonin @RheumNow https://t.co/s61WGBVK73 https://t.co/qhN95GdwgJ

• Role of Clinical and Laboratory Parameters in Differentiating Infection from Di…

@RheumNow #acr21 abst 195 prospective study of JAKi for refractory Still’s in 7 pts suggests JAKs can be useful as an add on but not in monotherapy : partial response 57%& failure in43%. No patient achieved complete remission. steroids could be decreased by63%~ https://t.co/rYHVReRHvL

Abst0254 #ACR21 @RheumNow CARRA SJIA cohort defines factors associated with medication free remission for ≥6 month-period: younger age, normal CRP levels & shorter time btw diagnosis and start of Rx. none of pts who developed MAS (3.9%) able to d/c Rx for ≥6 months

Polyautoimmunity: axSpA and Familial Mediterranean Fever by Dr. Rachel Tate ( @uptoTate ) Mysteries behind polyautoimmunity have confounded rheumatologists for decades. One such association, the co-existence of FMF and axSpA, remains rare. https://t.co/GbU1ikeyQw #ACR21 https://t.co/dRd6yxjieS

• https://bit.ly/2Ym6Jwz

Rare co-existence of FMF & axSpA significantly lowered age of axSpA symptom onset. Radiographic changes in FMF+axSpA suggested worse disease. Rate of amyloidosis and hip involvement were higher in FMF+axSpA pts. Abs 0378 #ACR21 #RheumNow @RheumNow https://t.co/lUmn3A90Ob https://t.co/n3kj8GcV1i

• Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloar…

Retrospective French study found adding JAKi may be helpful in refractory AOSD. No complete response noted and no beneficial effect as monotherapy. Possible difference between JAKi? Abs 0195 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/J8kLJpJ39o https://t.co/aVsfCQ8CyV

• JAK Inhibitors in Refractory Adult and Childhood-Onset Still's Disease - A…

RELIANCE observational interim analysis in PFS pts treated w/ CAN. 168 CAPS, TRAPS, HIDS/MKD and FMF pts enrolled starting 10/17 - 12/20. 101 pts experienced an AE, 9 drug-related SAE. See table below. Abs 1090 #ACR21 #RheumNow @RheumNow https://t.co/4ship1G1tY https://t.co/EFlgUGNXdD

• Long-term Safety of Canakinumab in Patients with Autoinflammatory Periodic Feve…

RELIANCE interim data shows efficacy & safety of long-term CAN in FMF. This observational study is a good start, but offers questions regarding dosing of CAN in this patient population. Abs 0192 #ACR21 #RheumNow @RheumNow https://t.co/46o7AnUVj2 https://t.co/7oAPovbukl

• Influence of Canakinumab Dosing on Efficacy and Safety of Long-term Treatment i…

RELIANCE interim data shows that long-term CAN is safe & effective in CAPS. Interestingly, investigators observed a trend toward updosing over standard dosing. Abs 0191 #ACR21 #RheumNow @RheumNow https://t.co/ik6dAEZjFf https://t.co/arqSEzuC6Q

• Influence of Canakinumab Dosing on Long-term Efficacy and Safety in Patients wi…